arrow
A

Ayumi Taguchi

the university of tokyo
H指数:29
被引数:3,169

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association of HPV16 E7-specific T cell responses in cervical lymphocytes and peripheral blood with regression of high-grade cervical intraepithelial neoplasia lesions

HPV16 E7特异性T细胞反应在宫颈淋巴细胞的消退与外周血中与高级别宫颈上皮内瘤变病变的关系

2026-10-070
PRE
Super homotypic targeting by surface engineering of extracellular vesicles

通过细胞外囊泡的表面工程实现超同型靶向

2026-07-220
OAAI
Tokishakuyakusan suppresses endometriosis and may be associated with improved fertility during attempts to conceive: A mouse model study

当归芍药散抑制子宫内膜异位症,并可能与在尝试受孕期间改善生育能力有关:一项小鼠模型研究

2026-07-010
PRE
Corrigendum to ‘Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02—A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC’ [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828]

对‘DESTINY-Lung02研究最终分析结果及患者报告结局—一项曲妥珠单抗德鲁克替康在HER2突变转移性非小细胞肺癌患者中的剂量盲法、随机、II期研究’[胸腔肿瘤学杂志 卷20 期12 (2025) 1814-1828]的勘误

2026-02-230
OAAI
Synthetic lethality from the combination of a histone methyltransferase SUV39H2 inhibitor and a poly (ADP-ribose) polymerase inhibitor for uterine leiomyosarcoma

组蛋白甲基转移酶SUV39H2抑制剂与聚(ADP-核糖)聚合酶抑制剂联合应用对子宫平滑肌肉瘤的合成致死效应

2025-12-160
OAAI
PLK1 or WEE1 inhibition targets homologous recombination repair proficiency in BRCA1/2 wild-type high-grade serous ovarian cancer

PLK1或WEE1抑制靶向BRCA1/2野生型高级别浆液性卵巢癌的同源重组修复能力

2025-12-070
OAAI
Elucidating Alterations in Viral and Human Gene Expression Due to Human Papillomavirus Integration by Using Multimodal RNA Sequencing

阐明由于人乳头瘤病毒整合导致病毒和人类基因表达变化的多模态RNA测序研究

2025-10-060
OAAI
Optimizing treatment for platinum-resistant ovarian clear cell carcinoma: Efficacy of gemcitabine and combination therapy with bevacizumab

优化铂类耐药卵巢透明细胞癌的治疗: 吉西他滨和贝伐单抗联合治疗的疗效

Cancer
IF5.1
2025-08-310
OAAI
Final analysis results and patient-reported outcomes from DESTINY-Lung02—a dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic non–small cell lung cancer

最终分析结果和患者报告结局来自DESTINY-Lung02——一项关于曲妥珠单抗德鲁替康在HER2突变型转移性非小细胞肺癌患者中的剂量盲法、随机、II期研究

2025-07-300
PREAI
Multifaceted profiling of virus-specific CD8 T cells reveals distinct immune signatures against cytomegalovirus infection states during pregnancy

对病毒特异性CD8 T细胞的多维度分析揭示了妊娠期间巨细胞病毒感染状态下的不同免疫特征

2025-05-010
OAAI
Low CD86 expression is a predictive biomarker for clinical response to the therapeutic human papillomavirus vaccine IGMKK16E7: results of a post hoc analysis
2024-09-200
OAAI
Integrated genomic/epigenomic analysis stratifies subtypes of clear cell ovarian carcinoma, highlighting their cellular origin

整合的基因组/表观基因组分析对透明细胞卵巢癌的亚型进行分层,突出其细胞起源

2024-08-131
OAAI
Phase I and II randomized clinical trial of an oral therapeutic vaccine targeting human papillomavirus for treatment of cervical intraepithelial neoplasia 2 and 3
2023-11-2410
OAAI
Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (HER2; ERBB2)mutant (HER2m) metastatic non-small cell lung cancer (mNSCLC): Subgroup analysis of DESTINYeLung02 (DL-02)
2023-11-011
PRE